title: Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer.
authors: Duke Clinical Research Institute, Duke Medicine, Durham, NC. Electronic address: thomas.povsic@duke.edu.
authors: Thomas J
authors: TJ
authors: Povsic
authors: University of Virginia, Charlottesville, Va.
authors: Monica G
authors: MG
authors: Lawrence
authors: Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland, Ohio.
authors: A Michael
authors: AM
authors: Lincoff
authors: Mount Sinai School of Medicine, New York, NY.
authors: Roxana
authors: R
authors: Mehran
authors: Regado Biosciences, Basking Ridge, NJ.
authors: Christopher P
authors: CP
authors: Rusconi
authors: Regado Biosciences, Basking Ridge, NJ.
authors: Steven L
authors: SL
authors: Zelenkofske
authors: Duke Clinical Research Institute, Duke Medicine, Durham, NC.
authors: Zhen
authors: Z
authors: Huang
authors: Sailstad and Associates, Inc, Durham, NC.
authors: Jeffrey
authors: J
authors: Sailstad
authors: Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada.
authors: Paul W
authors: PW
authors: Armstrong
authors: Université Paris-Diderot, Sorbonne Paris Cité, Paris, France; Assistance Publique-Hôpitaux de Paris, Paris, France; NHLI, Royal Brompton Hospital, Imperial College, London, United Kingdom.
authors: P Gabriel
authors: PG
authors: Steg
authors: University of Freiburg, Freiburg, Germany.
authors: Christoph
authors: C
authors: Bode
authors: University of Cincinnati College of Medicine, Cincinnati, Ohio.
authors: Richard C
authors: RC
authors: Becker
authors: Duke Clinical Research Institute, Duke Medicine, Durham, NC.
authors: John H
authors: JH
authors: Alexander
authors: Johns Hopkins Asthma and Allergy Center, Baltimore, Md.
authors: N Franklin
authors: NF
authors: Adkinson
authors: Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa.
authors: Arnold I
authors: AI
authors: Levinson
mesh_terms: D000906:Antibodies / Q000276:immunology*; D052157:Aptamers, Nucleotide / Q000276:immunology*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000276:immunology*; D015337:Multicenter Studies as Topic; D011092:Polyethylene Glycols / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000906:Antibodies; D052157:Aptamers, Nucleotide; C515724:RB 006; D011092:Polyethylene Glycols